| Name | Title | Contact Details |
|---|
The Ideal Protein Method is medically designed & developed, being consistent with evidence-based guidelines for weight loss management and maintenance. It is a weight loss solution for the obese and overweight patient, including those with metabolic syndrome. Ideal Protein puts forward a proven, four-part method that enables safe, effective weight loss, with a healthy lifestyle approach and a structured maintenance program to sustain weight loss success. The method targets the root causes of weight gain by reversing the imbalance of insulin that occurs with the typical Western diet. A healthier lifestyle education is a key component of all phases of the Ideal Protein Weight Loss Method, which features personalized, one-on-one coaching and a diet plan to promote losing fat while maintaining lean muscle mass. For a hospital, medical group or private medical practice, the Ideal Protein Method is a comprehensive turnkey program with no costs for training and implementation, and no long-term commitment. Offered through healthcare practitioners, trained clinics and centers, the Ideal Protein Weight Loss Method and products are now available in more than 3,000 clinics and centers throughout North America. Research demonstrating the results of the Ideal Protein Weight Loss Method has been presented at leading medical conferences such as the 9th Annual Obesity Summit at the Cleveland Clinic and the Annual Scientific Meeting of the National Obesity Society. For information on Ideal Protein, please visit our website. For details about incorporating Ideal Protein into your medical practice, visit our practitioner information pages for Physicians and Pharmacists.
TearLab Corporation develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation`s common shares trade on the NASDAQ Capital Market under the symbol `TEAR` and on the Toronto Stock Exchange under the symbol `TLB`. Dry Eye Disease (DED) is a chronic, progressive disease. Morgan Stanley’s Dry Eye Market Report (2003) estimates that 30 to 60 million Americans suffer from dry eye symptoms. Only 10 million are diagnosed with the disease. Millions more suffer worldwide. The TearLab™ Osmolarity System provides the first quantitative and objective diagnostic technology that allows doctors to effectively manage their dry eye patients. TearLab will allow practitioners to diagnosis DED patients early in the disease process allowing for early intervention. TearLab received the CE Mark for its TearLab Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 14 countries including the US.
PHS broke ground in August 2003 on a 212,000-square-foot facility on almost 12 acres in Fairfield, Calif. Occupancy was anticipated for late 2003 or early 2004.
Aseptico Inc is a Woodinville, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MAWD Pathology is a Kansas City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.